A comparative study of oral terbinafine versus oral terbinafine and griseofulvin in tinea

Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with clinical diagnosis of tinea corporis, tinea cruris or tinea faciei or a combination of these conditions
•2. Microscopic confirmation of diagnosis

•(a) pregnancy
•(b) lactation
•(c) tinea elsewhere, eg, onychomycosis
•(d) another skin disease at the same site
•(e) inability to come for follow up
•(f) intake of terbinafine or griseofulvin in past 1 month
•(g) history of allergy to terbinafine or griseofulvin
•(h) present history of liver, renal or ischemic heart disease
•(i) patients on treatment with drugs that have interaction with terbinafine or griseofulvin
•(j) patient requiring antihistamines due to co-existing skin diseases as urticaria
•(k) abnormal CBC (Hb <9, platelet count < 1 lakh), LFT, RFT, plasma glucose (fasting and postprandial), HbA1C, fasting lipid profile, urine routine and microscopy, ECG
•(l) patients on treatment from skin OPD who is satisfied with the treatment.

发起方

Institute of Medical Sciences